Back to News
Market Impact: 0.25
Elevar Submits EMA Marketing Application For Lirafugratinib In Cholangiocarcinoma
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Elevar Therapeutics, majority-owned by HLB Co., submitted a Marketing Authorisation Application to the European Medicines Agency for lirafugratinib as a second-line treatment for patients with advanced or metastatic disease. The filing advances the drug toward potential European commercialization, though regulatory approval remains uncertain.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- SpaceX loses bid to toss NAACP lawsuit over Memphis data center air pollution
- Binance’s $6.3 billion hack raises questions about crypto wallet safety
- Crypto industry pours more than $200 million into 2026 midterms to pressure Congress on favorable rules
- France braces for fresh unrest, government vows tough response
- Judge allows NAACP lawsuit over xAI data center pollution to move forward
- GM will pay $220m to settle claims it sold drivers’ Smart Driver data